{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:acoramidis",
  "owner": "cardio",
  "kind": "drug",
  "slug": "acoramidis",
  "name": "Acoramidis",
  "aliases": [
    "Attruby",
    "Acoramidis hydrochloride"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Acoramidis is the medicine in Attruby, a tablet sold as acoramidis hydrochloride. The US label calls it a transthyretin stabilizer and says it is a selective stabilizer of transthyretin (TTR), the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization. The atlas holds no trial results for it.",
  "summary_technical": "RxNorm ingredient 2698312 (acoramidis); the label names the salt acoramidis hydrochloride (RxNorm 2698313), whose UNII VY9C88C2NV is a broad match to the ingredient. RxClass lists the FDA established pharmacologic class Transthyretin Stabilizer, so the record is filed under the class page. MeSH has no descriptor for acoramidis (an exact-label lookup returned an empty list on 2026-11-19). The label read is the BridgeBio Pharma, Inc. label for Attruby, application NDA216540, effective 2026-06-29 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indication, the class and the mechanism sentences only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-19",
  "last_evidence_check": "2026-11-19",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "2698312",
      "normalized_value": "2698312",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "VY9C88C2NV",
      "normalized_value": "VY9C88C2NV",
      "match": "broad",
      "version": null,
      "label": "Acoramidis hydrochloride",
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "heart-failure"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says acoramidis is a selective stabilizer of transthyretin (TTR): it binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers."
  },
  "content_digest": "9eed0e120ec3b2f3557d5ed715dbb373f512c83990889481de2ce7da1ec29ac7",
  "review": {
    "content_digest": "9eed0e120ec3b2f3557d5ed715dbb373f512c83990889481de2ce7da1ec29ac7",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-attruby-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:acoramidis",
      "category": "descriptive",
      "statement": "The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.",
      "context": {
        "id": "cardio:ctx-fda-attruby-label-us",
        "label": "Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby",
        "recipient": "unknown",
        "population": "Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Not stated in the label passages read",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-19",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA216540.",
          "snapshot": {
            "id": "cardio:openfda-label-attruby-2026-11-19",
            "retrieved_at": "2026-11-19T00:29:51Z",
            "content_hash": "438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f",
            "source_effective_date": "2026-06-29",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-attruby",
            "source_type": "regulator",
            "title": "openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k28-openfda-label-acoramidis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260629.",
          "snapshot": {
            "id": "cardio:openfda-label-attruby-2026-11-19",
            "retrieved_at": "2026-11-19T00:29:51Z",
            "content_hash": "438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f",
            "source_effective_date": "2026-06-29",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-attruby",
            "source_type": "regulator",
            "title": "openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k28-openfda-label-acoramidis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], highlights sentence",
          "applicability_note": "Label passage quoted in the research quote table (Q-W4K28-ACO-LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-attruby-2026-11-19",
            "retrieved_at": "2026-11-19T00:29:51Z",
            "content_hash": "438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f",
            "source_effective_date": "2026-06-29",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-attruby",
            "source_type": "regulator",
            "title": "openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k28-openfda-label-acoramidis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], highlights sentence, benefit",
          "applicability_note": "Label passage quoted in the research quote table (Q-W4K28-ACO-LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-attruby-2026-11-19",
            "retrieved_at": "2026-11-19T00:29:51Z",
            "content_hash": "438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f",
            "source_effective_date": "2026-06-29",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-attruby",
            "source_type": "regulator",
            "title": "openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22913552ef-875d-4cb7-bf05-a7d20a394c38%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k28-openfda-label-acoramidis.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "b3dcc59157dae756df26320db13c408a6c26511f962d1ba181addc280e9a92e8",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-attruby-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Acoramidis is a transthyretin stabilizer (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:transthyretin-directed-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2698312-2026-11-19",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:cardiac-amyloidosis",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-attruby-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Both labels call the medicine a stabilizer of transthyretin, and both list the cardiomyopathy of transthyretin-mediated amyloidosis as the indication",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:tafamidis",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/acoramidis/",
  "context_path": "api/v1/context/cardio--acoramidis.md"
}
